تخطي إلى المحتوى

سيماجلوتيد و ReCET يقللان الحاجة إلى العلاج بالأنسولين لمرضى السكري

A groundbreaking study presented at UEG Week 2024 investigates a novel treatment strategy for type 2 diabetes (T2D) that has the potential to significantly reduce or even eliminate the need for insulin therapy[1]. This innovative approach combines a novel procedure called ReCET (Re-Cellularization via Electroporation Therapy) with the drug Semaglutide.

ReCET is a procedure performed under deep sedation that aims to improve the body's sensitivity to its own insulin[1]. Following the ReCET treatment, study participants followed a two-week isocaloric liquid diet before gradually starting Semaglutide, up to a dose of 1mg per week[1].

Semaglutide is a drug in the class of GLP-1 receptor agonists used to treat type 2 diabetes and as a weight-loss agent[3]. It works by increasing insulin secretion, decreasing glucagon release, delaying gastric emptying, and reducing appetite[4].

The study included 14 participants aged 28 to 75 years with a body mass index between 24 and 40 kg/m²[1]. The results were remarkable: at follow-ups at 6, 12, and 24 months, 86% of participants (12 out of 14) no longer required insulin therapy[1]. All patients maintained glycemic control, with HbA1c levels remaining below 7.5%[1].

This combination of ReCET and Semaglutide shows promising results in the treatment of T2D. Unlike conventional drug therapies that require daily intake, ReCET is a one-time procedure that addresses the issue of continuous patient adherence in T2D treatment[1]. Furthermore, the treatment is disease-modifying, as it improves the patient's insulin sensitivity, thus addressing the root cause of the disease[1].

Researchers are now planning larger randomized controlled trials to further validate these findings and better understand the underlying mechanism of ReCET[1].

Sources:
[1] Novel procedure combined with semaglutide may eliminate insulin … https://medicalxpress.com/news/2024-10-procedure-combined-semaglutide-insulin-diabetes.html
[2] Two-year effects of semaglutide in adults with overweight or obesity https://www.nature.com/articles/s41591-022-02026-4
[3] Semaglutide – Wikipedia https://en.wikipedia.org/wiki/Semaglutide
[4] Semaglutide: Uses, Dosage, Side Effects, Brands – Drugs.com https://www.drugs.com/semaglutide.html
[5] Semaglutide – StatPearls – NCBI Bookshelf https://www.ncbi.nlm.nih.gov/books/NBK603723/
[6] How does semaglutide work? – Mayo Clinic Diet https://diet.mayoclinic.org/us/blog/2024/how-does-semaglutide-work/

صورة رمزية للمؤلف
لاب نيوز ميديا ذ.م.م
رئيسي تحرير labnews.ai هما ماريتا فولبورن وفلاد جورجيسكو. وهما مؤلفان حققا أفضل المبيعات، وكاتبا علوم، وصحفيي علوم منذ عام 1994.مزيد من التفاصيل حول كتاباتهما على X-Press Journalistenbüro (https://xpress-journalisten.com).مزيد من المعلومات على ويكيبيديا:عن ماريتا: https://de.wikipedia.org/wiki/Marita_Vollborn عن فلاد: https://de.wikipedia.org/wiki/Vlad_Georgescu
لاب نيوز ميديا ذ.م.م

لاب نيوز ميديا ذ.م.م

رئيسي تحرير labnews.ai هما ماريتا فولبورن وفلاد جورجيسكو. وهما مؤلفان حققا أفضل المبيعات، وكاتبا علوم، وصحفيي علوم منذ عام 1994.مزيد من التفاصيل حول كتاباتهما على X-Press Journalistenbüro (https://xpress-journalisten.com).مزيد من المعلومات على ويكيبيديا:عن ماريتا: https://de.wikipedia.org/wiki/Marita_Vollborn عن فلاد: https://de.wikipedia.org/wiki/Vlad_Georgescu